Pulse Biosciences (NASDAQ:PLSE) is set to post its quarterly earnings results on Monday, March 12th.
Pulse Biosciences (NASDAQ PLSE) opened at $17.36 on Friday. Pulse Biosciences has a one year low of $9.81 and a one year high of $39.50. The company has a market capitalization of $281.25 and a P/E ratio of -12.40.
Several research analysts have recently commented on the company. BidaskClub downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. ValuEngine upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.
In other news, Director Maky Zanganeh purchased 4,000 shares of Pulse Biosciences stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average cost of $23.07 per share, for a total transaction of $92,280.00. Following the purchase, the director now directly owns 332,500 shares of the company’s stock, valued at approximately $7,670,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Pulse Biosciences (PLSE) Scheduled to Post Earnings on Monday” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.thelincolnianonline.com/2018/03/11/pulse-biosciences-plse-scheduled-to-post-earnings-on-monday.html.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.